JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
作者信息
Khan Sujoy, Durairaj Senthil
机构信息
Department of Immunology and Allergy, Hull University Teaching Hospitals NHS Trust, Queen's Center, Castle Hill Hospital, Cottingham, United Kingdom,
Department of Hematology and Hemato-Oncology, Hull University Teaching Hospitals NHS Trust, Queen's Center, Castle Hill Hospital, Cottingham, United Kingdom.
出版信息
Int Arch Allergy Immunol. 2020;181(7):563-564. doi: 10.1159/000508750. Epub 2020 May 26.
Abstract
摘要
相似文献
1
JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.使用甲氨蝶呤抑制JAK作为治疗新冠病毒病的方法是一把双刃剑。
Int Arch Allergy Immunol. 2020;181(7):563-564. doi: 10.1159/000508750. Epub 2020 May 26.
2
Low dose radiation therapy for COVID-19 pneumonia: A double-edged sword.低剂量放射治疗新冠病毒肺炎：一把双刃剑。
Radiother Oncol. 2020 Jun;147:224-225. doi: 10.1016/j.radonc.2020.04.026. Epub 2020 Apr 20.
3
Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword.回应：低剂量放射治疗新冠病毒肺炎——一把双刃剑
Radiother Oncol. 2020 Jun;147:226. doi: 10.1016/j.radonc.2020.04.042. Epub 2020 May 7.
4
Letter to the Editor: Social Media Is a Double-Edged Sword in the COVID-19 Pandemic.致编辑的信：社交媒体在新冠疫情中是一把双刃剑。
J Korean Med Sci. 2020 Jul 27;35(29):e270. doi: 10.3346/jkms.2020.35.e270.
5
Corticosteroid use for 2019-nCoV infection: A double-edged sword.2019新型冠状病毒感染中使用皮质类固醇：一把双刃剑。
Infect Control Hosp Epidemiol. 2020 Oct;41(10):1244-1245. doi: 10.1017/ice.2020.165. Epub 2020 Apr 23.
6
The Double-Edged Sword of Iranian Social Media Against COVID-19.伊朗社交媒体抗击新冠疫情的双刃剑
Prehosp Disaster Med. 2020 Aug;35(4):468-469. doi: 10.1017/S1049023X20000722. Epub 2020 May 21.
7
Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword?粒细胞集落刺激因子（G-CSF）与新型冠状病毒肺炎（COVID-19）：一把双刃剑？
Infez Med. 2020 Sep 1;28(3):459-460.
8
COVID-19 and Racism-a double edged dagger.新冠疫情与种族主义——一把双刃剑。
Lancet Diabetes Endocrinol. 2020 Aug;8(8):649. doi: 10.1016/S2213-8587(20)30243-6. Epub 2020 Jul 10.
9
The double edged interferon riddle in COVID-19 pathogenesis.新冠病毒发病机制中的双刃剑——干扰素之谜
Crit Care. 2020 Nov 1;24(1):631. doi: 10.1186/s13054-020-03337-z.
10
Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.JAK抑制剂与甲氨蝶呤或抗细胞因子生物制剂联合用于重症COVID-19患者
Int Arch Allergy Immunol. 2020;181(8):648-649. doi: 10.1159/000509198. Epub 2020 Jun 12.
引用本文的文献
1
DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action.二氢叶酸还原酶抑制剂对 SARS-CoV-2 表现出多效性的抗病毒活性：作用机制的见解。
Viruses. 2023 May 9;15(5):1128. doi: 10.3390/v15051128.
2
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.巴瑞替尼治疗 2019 冠状病毒病（COVID-19）的临床疗效和不良事件：系统评价和荟萃分析。
J Med Virol. 2022 Apr;94(4):1523-1534. doi: 10.1002/jmv.27482. Epub 2021 Dec 13.
3
Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.基于基因共表达网络分析的冠状病毒（SARS-CoV-2）药物再利用。
Sci Rep. 2021 Nov 8;11(1):21872. doi: 10.1038/s41598-021-01410-3.
4
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.癌症与SARS-CoV-2引发的炎症、重叠功能及药物靶向治疗
Inflammopharmacology. 2021 Apr;29(2):343-366. doi: 10.1007/s10787-021-00796-w. Epub 2021 Mar 15.
5
COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.新冠病毒肺炎：芦可替尼对炎症“逃逸”的高度抑制以避免细胞因子风暴
Front Oncol. 2021 Jan 8;10:599502. doi: 10.3389/fonc.2020.599502. eCollection 2020.
6
The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.炎症途径与 COVID-19 的相互作用：发病机制和治疗选择的批判性综述。
Microb Pathog. 2021 Jan;150:104673. doi: 10.1016/j.micpath.2020.104673. Epub 2020 Dec 2.
7
Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.JAK抑制剂与甲氨蝶呤或抗细胞因子生物制剂联合用于重症COVID-19患者
Int Arch Allergy Immunol. 2020;181(8):648-649. doi: 10.1159/000509198. Epub 2020 Jun 12.
本文引用的文献
1
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
2
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.严重 COVID-19 合并噬血细胞性淋巴组织细胞增生症患者对阿那白滞素的良好反应。
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1. doi: 10.1016/j.chom.2020.05.007. Epub 2020 May 14.
3
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.JAK 抑制作为 COVID-19 患者的一种新治疗策略。
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
4
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
5
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
6
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?COVID-19：慢性炎症性疾病中细胞因子靶向治疗的风险？
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
7
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.新冠病毒肺炎患者抗病毒淋巴细胞的功能耗竭
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
8
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK抑制作为免疫和炎症性疾病的一种治疗策略。
Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267.
9
How I treat CNS lymphomas.我是如何治疗中枢神经系统淋巴瘤的。
Blood. 2013 Oct 3;122(14):2318-30. doi: 10.1182/blood-2013-06-453084. Epub 2013 Aug 20.
Zotero 插件